Table 2.
Response to mepolizumab in patients stratified by baseline FeNO (25 and 50 ppb thresholds) and eosinophil count (150 and 300 cells/µL thresholds)
| Treatment response | Baseline FeNO 25 ppb and 150 EOs/µL thresholds | |||||||
| FeNO <25 ppb, | FeNO ≥25 ppb, | FeNO <25 ppb, | FeNO ≥25 ppb, | |||||
| <150 EOs/µL | <150 EOs/µL | ≥150 EOs/µL | ≥150 EOs/µL | |||||
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | |
| Exacerbations in the previous 12 months | ||||||||
| Baseline | 8 | 4.9 (4.0) | 11 | 3.8 (2.9) | 51 | 3.9 (3.4) | 152 | 4.4 (3.6) |
| 12 months | 8 | 2.4 (1.4) | 11 | 0.6 (0.9) | 51 | 0.9 (1.0) | 152 | 0.8 (1.3) |
| Prebronchodilator FEV1, L | ||||||||
| Baseline | 6 | 1.7 (0.9) | 8 | 2.1 (0.8) | 43 | 1.7 (0.6) | 132 | 1.9 (0.8) |
| 12 months | 3 | 2.0 (0.5) | 7 | 2.3 (0.8) | 34 | 1.9 (0.6) | 109 | 2.2 (0.8) |
| Postbronchodilator FEV1, L | ||||||||
| Baseline | 5 | 1.8 (0.7) | 8 | 1.8 (0.8) | 37 | 1.9 (0.5) | 99 | 2.1 (0.8) |
| 12 months | 5 | 1.6 (0.5) | 7 | 2.2 (1.0) | 26 | 1.9 (0.5) | 65 | 2.3 (0.8) |
| Prednisolone dose in the last month, mg/day | ||||||||
| Baseline | 3 | 16.4 (12.1) | 5 | 8.6 (7.1) | 18 | 8.3 (6.8) | 47 | 11.7 (10.0) |
| 12 months | 3 | 3.2 (2.8) | 5 | 5.0 (4.7) | 17 | 2.4 (3.4) | 41 | 3.7 (6.9) |
| ACT score | ||||||||
| Baseline | 6 | 17.5 (6.8) | 8 | 13.1 (5.2) | 46 | 13.8 (5.4) | 147 | 14.4 (5.0) |
| 12 months | 4 | 18.3 (6.1) | 7 | 20.9 (3.2) | 44 | 20.3 (4.1) | 131 | 21.2 (3.9) |
| Treatment response | Baseline FeNO 25 ppb and 300 EOs/µL thresholds | |||||||
| FeNO <25 ppb, | FeNO ≥25 ppb, | FeNO <25 ppb, | FeNO ≥25 ppb, | |||||
| <300 EOs/µL | <300 EOs/µL | ≥300 EOs/µL | ≥300 EOs/µL | |||||
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | |
| Exacerbations in the previous 12 months | ||||||||
| Baseline | 17 | 3.7 (3.1) | 19 | 4.4 (3.1) | 42 | 4.1 (3.5) | 144 | 4.3 (3.6) |
| 12 months | 17 | 1.7 (1.3) | 19 | 0.9 (1.3) | 42 | 0.8 (1.0) | 144 | 0.8 (1.3) |
| Prebronchodilator FEV1, L | ||||||||
| Baseline | 12 | 1.8 (0.8) | 16 | 2.0 (0.8) | 37 | 1.7 (0.6) | 124 | 1.9 (0.8) |
| 12 months | 7 | 2.1 (0.6) | 14 | 2.1 (1.0) | 30 | 1.8 (0.5) | 102 | 2.2 (0.7) |
| Postbronchodilator FEV1, L | ||||||||
| Baseline | 14 | 1.8 (0.6) | 11 | 2.1 (0.9) | 28 | 1.9 (0.5) | 96 | 2.1 (0.8) |
| 12 months | 10 | 1.7 (0.4) | 10 | 2.3 (1.0) | 21 | 1.9 (0.5) | 62 | 2.2 (0.7) |
| Prednisolone dose in the last month, mg/day | ||||||||
| Baseline | 7 | 10.2 (8.7) | 12 | 6.9 (5.8) | 16 | 9.3 (7.1) | 57 | 10.9 (9.4) |
| 12 months | 8 | 2.5 (2.5) | 12 | 5.2 (8.3) | 16 | 2.7 (4.2) | 51 | 2.8 (5.0) |
| ACT score | ||||||||
| Baseline | 14 | 16.4 (4.9) | 15 | 13.1 (5.2) | 38 | 13.4 (5.6) | 140 | 14.5 (5.0) |
| 12 months | 12 | 19.3 (4.5) | 14 | 19.4 (5.7) | 36 | 20.4 (4.1) | 124 | 21.4 (3.5) |
| Treatment response | Baseline FeNO 50 ppb and 300 EOs/µL thresholds | |||||||
| FeNO <50 ppb, | FeNO ≥50 ppb, | FeNO <50 ppb, | FeNO ≥50 ppb, | |||||
| <300 EOs/µL | <300 EOs/µL | ≥300 EOs/µL | ≥300 EOs/µL | |||||
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | |
| Exacerbations in the previous 12 months | ||||||||
| Baseline | 24 | 3.6 (3.5) | 12 | 4.9 (2.5) | 99 | 4.2 (3.6) | 87 | 4.5 (3.6) |
| 12 months | 24 | 1.6 (1.5) | 12 | 0.6 (0.8) | 99 | 0.8 (1.1) | 87 | 0.9 (1.3) |
| Prebronchodilator FEV1, L | ||||||||
| Baseline | 17 | 1.9 (0.8) | 11 | 2.0 (0.9) | 88 | 1.8 (0.8) | 73 | 2.0 (0.7) |
| 12 months | 10 | 2.1 (0.8) | 11 | 2.1 (1.0) | 74 | 1.9 (0.7) | 58 | 2.4 (0.7) |
| Postbronchodilator FEV1, L | ||||||||
| Baseline | 19 | 1.9 (0.7) | 6 | 2.2 (1.0) | 69 | 2.0 (0.7) | 55 | 2.2 (0.8) |
| 12 months | 14 | 1.9 (0.8) | 6 | 2.4 (0.9) | 46 | 1.9 (0.5) | 37 | 2.5 (0.8) |
| Prednisolone dose in the last month, mg/day | ||||||||
| Baseline | 9 | 9.4 (8.5) | 6 | 8.5 (7.7) | 29 | 9.7 (7.5) | 29 | 12.9 (11.2) |
| 12 months | 9 | 3.0 (3.0) | 6 | 8.3 (11.4) | 26 | 2.8 (5.2) | 25 | 3.1 (5.4) |
| ACT score | ||||||||
| Baseline | 19 | 15.7 (5.4) | 10 | 12.9 (5.2) | 92 | 14.6 (5.5) | 86 | 13.8 (4.7) |
| 12 months | 16 | 18.9 (5.5) | 10 | 20.1 (5.1) | 85 | 21.4 (3.5) | 75 | 21.0 (3.9) |
ACT, Asthma Control Test; EOs, eosinophils; FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s.